Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice
Maya Kansara, Michael Tsang, Laurent Kodjabachian, Natalie A Sims, Melanie K Trivett, Mathias Ehrich, Alexander Dobrovic, John Slavin, Peter FM Choong, Paul J Simmons, Igor B Dawid, David M Thomas
Journal of Clinical Investigation | AMER SOC CLINICAL INVESTIGATION INC | Published : 2009
Awarded by National Health and Medical Research Council
The authors would like to thank colleagues in the Bowtell and Thomas laboratories for helpful discussions and Alexander Grinberg, Andreas Tomac, Heiner Westphal, Martha Rebbert, and Paul Love for help in generating gene-modified mice. We thank Carleen Cullinane and staff for PET scanning of the mice. This work was supported by grants 350432 and 508982 from the National Health and Medical Research Council, by the Cancer Council Victoria, by the Sarcoma Foundation of America, by and the intramural Research Program of the NICHD, NIH. D.M. Thomas was supported by R.D. Wright Career Development Award 2003-7 and by Victorian Cancer Agency Clinician Researcher Fellowship 2008-10.